200 related articles for article (PubMed ID: 30096190)
1. Persistently elevated soluble MHC class I polypeptide-related sequence A and transforming growth factor-β1 levels are poor prognostic factors in head and neck squamous cell carcinoma after definitive chemoradiotherapy.
Chen JL; Chang CC; Huang YS; Kuo HY; Chen TY; Wang CW; Kuo SH; Lin YL
PLoS One; 2018; 13(8):e0202224. PubMed ID: 30096190
[TBL] [Abstract][Full Text] [Related]
2. High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy.
Chandrasekara S; Davis S; Thomson P; Haydon A
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e442-e447. PubMed ID: 29345108
[TBL] [Abstract][Full Text] [Related]
3. High expression of MLANA in the plasma of patients with head and neck squamous cell carcinoma as a predictor of tumor progression.
Rodrigues-Junior DM; Tan SS; Lim SK; de Souza Viana L; Carvalho AL; Vettore AL; Iyer NG
Head Neck; 2019 May; 41(5):1199-1205. PubMed ID: 30803092
[TBL] [Abstract][Full Text] [Related]
4. Impact of smoking cessation on clinical outcomes in patients with head and neck squamous cell carcinoma receiving curative chemoradiotherapy: A prospective study.
Chen JL; Shen CW; Wang CC; Huang YS; Chen JP; Chiang CH; Lin YL; Kuo SH; Wang CW
Head Neck; 2019 Sep; 41(9):3201-3210. PubMed ID: 31116482
[TBL] [Abstract][Full Text] [Related]
5. Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy.
Ou D; Adam J; Garberis I; Blanchard P; Nguyen F; Levy A; Casiraghi O; Gorphe P; Breuskin I; Janot F; Temam S; Scoazec JY; Deutsch E; Tao Y
Radiother Oncol; 2019 Jan; 130():89-96. PubMed ID: 30172455
[TBL] [Abstract][Full Text] [Related]
6. Circulating extracellular vesicle-associated TGFβ3 modulates response to cytotoxic therapy in head and neck squamous cell carcinoma.
Rodrigues-Junior DM; Tan SS; Lim SK; Leong HS; Melendez ME; Ramos CRN; Viana LS; Tan DSW; Carvalho AL; Iyer NG; Vettore AL
Carcinogenesis; 2019 Dec; 40(12):1452-1461. PubMed ID: 31436806
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of PET/CT with (18)F-fluoroazomycin arabinoside for patients with head and neck squamous cell carcinomas receiving chemoradiotherapy.
Saga T; Inubushi M; Koizumi M; Yoshikawa K; Zhang MR; Obata T; Tanimoto K; Harada R; Uno T; Fujibayashi Y
Ann Nucl Med; 2016 Apr; 30(3):217-24. PubMed ID: 26662072
[TBL] [Abstract][Full Text] [Related]
8. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation.
Bojaxhiu B; Templeton AJ; Elicin O; Shelan M; Zaugg K; Walser M; Giger R; Aebersold DM; Dal Pra A
Radiat Oncol; 2018 Nov; 13(1):216. PubMed ID: 30400969
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids.
Klöss S; Chambron N; Gardlowski T; Weil S; Koch J; Esser R; Pogge von Strandmann E; Morgan MA; Arseniev L; Seitz O; Köhl U
Front Immunol; 2015; 6():543. PubMed ID: 26579120
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of serum sMICA levels in non-small cell lung cancer.
Wang LP; Niu H; Xia YF; Han YL; Niu P; Wang HY; Zhou QL
Eur Rev Med Pharmacol Sci; 2015 Jun; 19(12):2226-30. PubMed ID: 26166647
[TBL] [Abstract][Full Text] [Related]
11. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
[TBL] [Abstract][Full Text] [Related]
12. Roles of Ki-67 and p16 as biomarkers for unknown primary head and neck squamous cell carcinoma.
Maebayashi T; Ishibashi N; Aizawa T; Sakaguchi M; Saito T; Kawamori J; Tanaka Y; Hirotani Y; Homma T
Eur Arch Otorhinolaryngol; 2019 Apr; 276(4):1221-1229. PubMed ID: 30756227
[TBL] [Abstract][Full Text] [Related]
13. Serum Transforming Growth Factor-β1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy.
Lu SL; Hsu FM; Tsai CL; Wu JK; Lee JM; Huang PM; Hsu CH; Koong AC; Chang DT; Cheng JC
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1023-31. PubMed ID: 26475065
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of nutritional and hematologic markers in head and neck squamous cell carcinoma treated by chemoradiotherapy.
Moon H; Roh JL; Lee SW; Kim SB; Choi SH; Nam SY; Kim SY
Radiother Oncol; 2016 Feb; 118(2):330-4. PubMed ID: 26653356
[TBL] [Abstract][Full Text] [Related]
15. Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
Tao Y; Aupérin A; Graff P; Lapeyre M; Grégoire V; Maingon P; Geoffrois L; Verrelle P; Calais G; Gery B; Martin L; Alfonsi M; Deprez P; Bardet E; Pignon T; Rives M; Sire C; Bourhis J
Oral Oncol; 2017 Aug; 71():61-66. PubMed ID: 28688693
[TBL] [Abstract][Full Text] [Related]
16. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus infection and plasma transforming growth factor-beta1 levels in head and neck cancers.
Chen HW; Yang SF; Chang YC; Wang TY; Chen YJ; Hwang JJ
Acta Otolaryngol; 2008 Oct; 128(10):1145-51. PubMed ID: 18720060
[TBL] [Abstract][Full Text] [Related]
18. High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma.
Samuels S; Ferns DM; Meijer D; van Straalen JP; Buist MR; Zijlmans HJ; Kenter GG; Jordanova ES
Tissue Antigens; 2015 Jun; 85(6):476-83. PubMed ID: 25871737
[TBL] [Abstract][Full Text] [Related]
19. Post-treatment plasma transforming growth factor beta 1 (TGF-beta1) level predicts for late morbidity in patients with advanced head and neck cancer.
Feltl D; Závadová E; Pála M; Hozák P
Neoplasma; 2005; 52(5):393-7. PubMed ID: 16151583
[TBL] [Abstract][Full Text] [Related]
20. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
Chang CL; Yuan KS; Wu SY
Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
